{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:21:52Z","timestamp":1793481712487,"version":"4.5.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003521","name":"Department of Education, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019111","name":"Perron Institute for Neurological and Translational Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008710","name":"Dementia Australia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royce Simmons Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder defined by motor impairments. However, people with PD (PwPD) experience a defined spectrum of non-motor symptoms, with gastrointestinal dysfunction the most common and earliest-presenting. Evidence suggests that PD pathology may originate in the gut, where microbial dysbiosis and immune dysregulation contribute to neuroinflammation, although mechanisms underlying this are unclear. PwPD (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931) and healthy controls (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200928) were evaluated for clinical and gastrointestinal symptoms, faecal and plasma sample metabolomics, and comprehensive blood immunophenotyping. In PwPD, faecal samples exhibited reduced glutamate, succinate, and uracil concentrations, while plasma showed decreased 3-hydroxybutyrate and elevated creatine, succinate, and alanine levels. Immunophenotyping revealed a reduction in T cells, with evidence of altered effector capacity and functionality in CD4, CD8, MAIT and V\u03b42 compartments. NK cells were expanded, while B cells were decreased in frequency with an enrichment of memory-like cells. Immune perturbations were correlated with levels of immunomodulatory metabolite succinate. Finally, clustering of blood parameters identified two PD endophenotypes distinguishable by gastrointestinal symptoms and T cell phenotypes associated with gut- and brain-tropism. These findings contribute to the growing understanding of metabolite-associated immune dysregulation in PD and highlight potential targets for early intervention in individuals presenting with gastrointestinal dysfunction.\n                  <\/jats:p>","DOI":"10.1038\/s41531-025-01212-8","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T06:16:23Z","timestamp":1766211383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune and metabolic signatures characterise constipation-driven endophenotypes in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Abbey","family":"Figliomeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Abonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Kenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Whiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome D.","family":"Coudert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Kaskow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Anderton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"1212_CR1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","volume":"72","author":"AJ Noyce","year":"2012","unstructured":"Noyce, A. J. et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 72, 893\u2013901 (2012).","journal-title":"Ann. Neurol."},{"key":"1212_CR2","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.0b013e3181c34af5","volume":"73","author":"R Savica","year":"2009","unstructured":"Savica, R. et al. Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology 73, 1752\u20131758 (2009).","journal-title":"Neurology"},{"key":"1212_CR3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","volume":"396","author":"H Braak","year":"2006","unstructured":"Braak, H., de Vos, R. A., Bohl, J. & Del Tredici, K. Gastric \u03b1-synuclein immunoreactive inclusions in Meissner\u2019s and Auerbach\u2019s plexuses in cases staged for Parkinson\u2019s disease-related brain pathology. Neurosci. Lett. 396, 67\u201372 (2006).","journal-title":"Neurosci. Lett."},{"key":"1212_CR4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-013-1214-6","volume":"127","author":"D Hilton","year":"2014","unstructured":"Hilton, D. et al. Accumulation of \u03b1-synuclein in the bowel of patients in the pre-clinical phase of Parkinson\u2019s disease. Acta Neuropathol. 127, 235\u2013241 (2014).","journal-title":"Acta Neuropathol."},{"key":"1212_CR5","doi-asserted-by":"crossref","first-page":"e12728","DOI":"10.1371\/journal.pone.0012728","volume":"5","author":"T Lebouvier","year":"2010","unstructured":"Lebouvier, T. et al. Colonic biopsies to assess the neuropathology of Parkinson\u2019s disease and its relationship with symptoms. PLoS ONE 5, e12728 (2010).","journal-title":"PLoS ONE"},{"key":"1212_CR6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/mds.25020","volume":"27","author":"KM Shannon","year":"2012","unstructured":"Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S. & Kordower, J. H. Is alpha-synuclein in the colon a biomarker for premotor Parkinson\u2019s disease? evidence from 3 cases. Mov. Disord. 27, 716\u2013719 (2012).","journal-title":"Mov. Disord."},{"key":"1212_CR7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","volume":"33","author":"CH Hawkes","year":"2007","unstructured":"Hawkes, C. H., Del Tredici, K. & Braak, H. Parkinson\u2019s disease: a dual-hit hypothesis. Neuropathol. Appl Neurobiol. 33, 599\u2013614 (2007).","journal-title":"Neuropathol. Appl Neurobiol."},{"key":"1212_CR8","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"1212_CR9","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer, P. & Van Den Berge, N. Brain-first versus gut-first parkinson\u2019s disease: a hypothesis. J. Parkinsons Dis. 9, S281\u2013s295 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"1212_CR10","doi-asserted-by":"crossref","unstructured":"Dumitrescu, L. et al. Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in parkinson\u2019s disease. Front. Neurosci. 15, 689723 (2021).","DOI":"10.3389\/fnins.2021.689723"},{"key":"1212_CR11","doi-asserted-by":"crossref","first-page":"e28032","DOI":"10.1371\/journal.pone.0028032","volume":"6","author":"CB Forsyth","year":"2011","unstructured":"Forsyth, C. B. et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson\u2019s disease. PLoS ONE 6, e28032 (2011).","journal-title":"PLoS ONE"},{"key":"1212_CR12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/MIB.0000000000000735","volume":"22","author":"JC Lin","year":"2016","unstructured":"Lin, J. C., Lin, C. S., Hsu, C. W., Lin, C. L. & Kao, C. H. Association between Parkinson\u2019s disease and inflammatory bowel disease: a nationwide Taiwanese retrospective cohort study. Inflamm. Bowel Dis. 22, 1049\u20131055 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"1212_CR13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00702-016-1612-8","volume":"123","author":"XL Niu","year":"2016","unstructured":"Niu, X. L. et al. Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson\u2019s disease. J. Neural Transm. (Vienna) 123, 1381\u20131386 (2016).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"1212_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","volume":"7","author":"S Romano","year":"2021","unstructured":"Romano, S. et al. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 7, 27 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"1212_CR15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.parkreldis.2014.12.009","volume":"21","author":"AH Tan","year":"2015","unstructured":"Tan, A. H. et al. Helicobacter pylori infection is associated with worse severity of Parkinson\u2019s disease. Parkinson. Relat. Disord. 21, 221\u2013225 (2015).","journal-title":"Parkinson. Relat. Disord."},{"key":"1212_CR16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.dld.2018.09.017","volume":"51","author":"F Zhu","year":"2019","unstructured":"Zhu, F. et al. The risk of Parkinson\u2019s disease in inflammatory bowel disease: a systematic review and meta-analysis. Dig. Liver Dis. 51, 38\u201342 (2019).","journal-title":"Dig. Liver Dis."},{"key":"1212_CR17","doi-asserted-by":"crossref","unstructured":"Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A. & Kraneveld, A. D. Exploring Braak\u2019s hypothesis of Parkinson\u2019s disease. Front. Neurol. 8, 37 (2017).","DOI":"10.3389\/fneur.2017.00037"},{"key":"1212_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neulet.2017.03.045","volume":"648","author":"S Chen","year":"2017","unstructured":"Chen, S. et al. Increased abundance of myeloid-derived suppressor cells and Th17 cells in peripheral blood of newly-diagnosed Parkinson\u2019s disease patients. Neurosci. Lett. 648, 21\u201325 (2017).","journal-title":"Neurosci. Lett."},{"key":"1212_CR19","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/brain\/awae177","volume":"147","author":"C Roodveldt","year":"2024","unstructured":"Roodveldt, C. et al. The immune system in Parkinson\u2019s disease: what we know so far. Brain 147, 3306\u20133324 (2024).","journal-title":"Brain"},{"key":"1212_CR20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey, M. G. et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22, 657\u2013673 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1212_CR21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/ene.13206","volume":"24","author":"JS Kim","year":"2017","unstructured":"Kim, J. S. et al. Normal \u2018heart\u2019 in Parkinson\u2019s disease: is this a distinct clinical phenotype?. Eur. J. Neurol. 24, 349\u2013356 (2017).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","volume":"115","author":"L Parkkinen","year":"2008","unstructured":"Parkkinen, L., Pirttil\u00e4, T. & Alafuzoff, I. Applicability of current staging\/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 115, 399\u2013407 (2008).","journal-title":"Acta Neuropathol."},{"key":"1212_CR23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00401-019-02071-3","volume":"138","author":"A Raunio","year":"2019","unstructured":"Raunio, A. et al. Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85. Acta Neuropathol. 138, 771\u2013782 (2019).","journal-title":"Acta Neuropathol."},{"key":"1212_CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mdc3.13134","volume":"8","author":"JE Kenna","year":"2021","unstructured":"Kenna, J. E. et al. Characterization of gastrointestinal symptom type and severity in parkinson\u2019s disease: a case-control study in an australian cohort. Mov. Disord. Clin. Pr. 8, 245\u2013253 (2021).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"1212_CR25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0404.1994.tb02699.x","volume":"90","author":"U Fiszer","year":"1994","unstructured":"Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V. & Link, H. Parkinson\u2019s disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol. Scand. 90, 160\u2013166 (1994).","journal-title":"Acta Neurol. Scand."},{"key":"1212_CR26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"JA Saunders","year":"2012","unstructured":"Saunders, J. A. et al. CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J. Neuroimmune Pharm. 7, 927\u2013938 (2012).","journal-title":"J. Neuroimmune Pharm."},{"key":"1212_CR27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jneuroim.2012.07.015","volume":"252","author":"CH Stevens","year":"2012","unstructured":"Stevens, C. H. et al. Reduced T helper and B lymphocytes in Parkinson\u2019s disease. J. Neuroimmunol. 252, 95\u201399 (2012).","journal-title":"J. Neuroimmunol."},{"key":"1212_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43053-0","volume":"14","author":"CM Capelle","year":"2023","unstructured":"Capelle, C. M. et al. Early-to-mid stage idiopathic Parkinson\u2019s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females. Nat. Commun. 14, 7461 (2023).","journal-title":"Nat. Commun."},{"key":"1212_CR29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41421-021-00280-3","volume":"7","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson\u2019s disease. Cell Discov. 7, 52 (2021).","journal-title":"Cell Discov."},{"key":"1212_CR30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/intimm\/13.4.593","volume":"13","author":"JE Christensen","year":"2001","unstructured":"Christensen, J. E., Andreasen, S. \u00d8, Christensen, J. P. & Thomsen, A. R. CD11b expression as a marker to distinguish between recently activated effector CD8+ T cells and memory cells. Int. Immunol. 13, 593\u2013600 (2001).","journal-title":"Int. Immunol."},{"key":"1212_CR31","doi-asserted-by":"crossref","first-page":"900","DOI":"10.4049\/jimmunol.166.2.900","volume":"166","author":"S Fiorentini","year":"2001","unstructured":"Fiorentini, S. et al. CD11b expression identifies CD8+CD28+ T lymphocytes with phenotype and function of both naive\/memory and Effector cells1. J. Immunol. 166, 900\u2013907 (2001).","journal-title":"J. Immunol."},{"key":"1212_CR32","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.4049\/jimmunol.149.4.1326","volume":"149","author":"HI McFarland","year":"1992","unstructured":"McFarland, H. I., Nahill, S. R., Maciaszek, J. W. & Welsh, R. M. CD11b (Mac-1): a marker for CD8+ cytotoxic T cell activation and memory in virus infection. J. Immunol. 149, 1326\u20131333 (1992).","journal-title":"J. Immunol."},{"key":"1212_CR33","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1007\/s00262-021-02939-y","volume":"70","author":"W Rodin","year":"2021","unstructured":"Rodin, W. et al. Exhaustion in tumor-infiltrating mucosal-associated invariant T (MAIT) cells from colon cancer patients. Cancer Immunol. Immunother. 70, 3461\u20133475 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"1212_CR34","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/jgh.13242","volume":"31","author":"K Haga","year":"2016","unstructured":"Haga, K. et al. MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. J. Gastroenterol. Hepatol. 31, 965\u2013972 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1212_CR35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ni.3854","volume":"18","author":"O Rouxel","year":"2017","unstructured":"Rouxel, O. et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat. Immunol. 18, 1321\u20131331 (2017).","journal-title":"Nat. Immunol."},{"key":"1212_CR36","doi-asserted-by":"crossref","unstructured":"Souter, M. N. T. et al. CD8 coreceptor engagement of MR1 enhances antigen responsiveness by human MAIT and other MR1-reactive T cells. J. Exp. Med. 219, e20210828 (2022).","DOI":"10.1084\/jem.20210828"},{"key":"1212_CR37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/imcb.12021","volume":"96","author":"NA Gherardin","year":"2018","unstructured":"Gherardin, N. A. et al. Human blood MAIT cell subsets defined using MR1 tetramers. Immunol. Cell Biol. 96, 507\u2013525 (2018).","journal-title":"Immunol. Cell Biol."},{"key":"1212_CR38","doi-asserted-by":"crossref","unstructured":"Shi, L. et al. Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy. J. Immunother. Cancer 11, e005902 (2023).","DOI":"10.1136\/jitc-2022-005902"},{"key":"1212_CR39","doi-asserted-by":"crossref","unstructured":"Khuzwayo, S. et al. MR1-restricted MAIT cells from the human lung mucosal surface have distinct phenotypic, functional, and transcriptomic features that are preserved in HIV Infection. Front. Immunol. 12, 631410 (2021).","DOI":"10.3389\/fimmu.2021.631410"},{"key":"1212_CR40","doi-asserted-by":"crossref","first-page":"14378","DOI":"10.1073\/pnas.1611098113","volume":"113","author":"PL Ryan","year":"2016","unstructured":"Ryan, P. L. et al. Heterogeneous yet stable V\u03b42(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc. Natl. Acad. Sci. USA 113, 14378\u201314383 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1212_CR41","volume":"8","author":"MS Davey","year":"2017","unstructured":"Davey, M. S. et al. Clonal selection in the human V\u03b41 T cell repertoire indicates \u03b3\u03b4 TCR-dependent adaptive immune surveillance. Nat. Commun. 8, 14760 (2017).","journal-title":"Nat. Commun."},{"key":"1212_CR42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/imcb.12623","volume":"101","author":"A von Borstel","year":"2023","unstructured":"von Borstel, A. et al. Circulating effector \u03b3\u03b4 T cell populations are associated with acute coronavirus disease 19 in unvaccinated individuals. Immunol. Cell Biol. 101, 321\u2013332 (2023).","journal-title":"Immunol. Cell Biol."},{"key":"1212_CR43","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.3389\/fimmu.2018.02692","volume":"9","author":"MD Martin","year":"2018","unstructured":"Martin, M. D. & Badovinac, V. P. Defining memory CD8 T cell. Front Immunol. 9, 2692 (2018).","journal-title":"Front Immunol."},{"key":"1212_CR44","doi-asserted-by":"crossref","unstructured":"Cazzetta, V. et al. NKG2A expression identifies a subset of human V\u03b42 T cells exerting the highest antitumor effector functions. Cell Rep. 37, 109871 (2021).","DOI":"10.1016\/j.celrep.2021.109871"},{"key":"1212_CR45","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00853-9","volume":"9","author":"S Terzoli","year":"2024","unstructured":"Terzoli, S. et al. Expansion of memory V\u03b42 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics. npj Vaccines 9, 63 (2024).","journal-title":"npj Vaccines"},{"key":"1212_CR46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4 (2021).","journal-title":"Mol. Neurodegener."},{"key":"1212_CR47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41531-021-00239-x","volume":"7","author":"S Klatt","year":"2021","unstructured":"Klatt, S. et al. A six-metabolite panel as potential blood-based biomarkers for Parkinson\u2019s disease. NPJ Parkinsons Dis. 7, 94 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"1212_CR48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","volume":"87","author":"T Hatano","year":"2016","unstructured":"Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P. & Hattori, N. Identification of novel biomarkers for Parkinson\u2019s disease by metabolomic technologies. J. Neurol. Neurosurg. Psychiatry 87, 295\u2013301 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1212_CR49","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.4049\/jimmunol.180.6.3739","volume":"180","author":"MTM Vossen","year":"2008","unstructured":"Vossen, M. T. M. et al. CD27 defines phenotypically and functionally different human NK cell subsets. J. Immunol. 180, 3739\u20133745 (2008).","journal-title":"J. Immunol."},{"key":"1212_CR50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/imm.13634","volume":"169","author":"D Sharygin","year":"2023","unstructured":"Sharygin, D., Koniaris, L. G., Wells, C., Zimmers, T. A. & Hamidi, T. Role of CD14 in human disease. Immunology 169, 260\u2013270 (2023).","journal-title":"Immunology"},{"key":"1212_CR51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41577-021-00618-8","volume":"22","author":"D Zhivaki","year":"2022","unstructured":"Zhivaki, D. & Kagan, J. C. Innate immune detection of lipid oxidation as a threat assessment strategy. Nat. Rev. Immunol. 22, 322\u2013330 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1212_CR52","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/iai.64.5.1762-1769.1996","volume":"64","author":"R Landmann","year":"1996","unstructured":"Landmann, R. et al. Human monocyte CD14 is upregulated by lipopolysaccharide. Infect. Immun. 64, 1762\u20131769 (1996).","journal-title":"Infect. Immun."},{"key":"1212_CR53","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3389\/fimmu.2019.02035","volume":"10","author":"TS Kapellos","year":"2019","unstructured":"Kapellos, T. S. et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 10, 2035 (2019).","journal-title":"Front Immunol."},{"key":"1212_CR54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1212_CR55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41531-021-00188-5","volume":"7","author":"AD Thome","year":"2021","unstructured":"Thome, A. D. et al. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson\u2019s disease. NPJ Parkinsons Dis. 7, 41 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"1212_CR56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000494435","volume":"25","author":"V Bagheri","year":"2018","unstructured":"Bagheri, V., Khorramdelazad, H., Hassanshahi, G., Moghadam-Ahmadi, A. & Vakilian, A. CXCL12 and CXCR4 in the peripheral blood of patients with Parkinson\u2019s disease. Neuroimmunomodulation 25, 201\u2013205 (2018).","journal-title":"Neuroimmunomodulation"},{"key":"1212_CR57","volume":"16","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. CXCL12 is involved in \u03b1-synuclein-triggered neuroinflammation of Parkinson\u2019s disease. J. Neuroinflamm. 16, 263 (2019).","journal-title":"J. Neuroinflamm."},{"key":"1212_CR58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12640-009-9076-3","volume":"16","author":"M Shimoji","year":"2009","unstructured":"Shimoji, M., Pagan, F., Healton, E. B. & Mocchetti, I. CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson\u2019s disease. Neurotox. Res. 16, 318\u2013328 (2009).","journal-title":"Neurotox. Res."},{"key":"1212_CR59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578154","volume":"382","author":"J Holbrook","year":"2023","unstructured":"Holbrook, J. et al. Natural killer cells have an activated profile in early Parkinson\u2019s disease. J. Neuroimmunol. 382, 578154 (2023).","journal-title":"J. Neuroimmunol."},{"key":"1212_CR60","doi-asserted-by":"crossref","first-page":"637","DOI":"10.21037\/atm.2019.10.105","volume":"7","author":"C Sun","year":"2019","unstructured":"Sun, C. et al. Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson\u2019s disease. Ann. Transl. Med 7, 637 (2019).","journal-title":"Ann. Transl. Med"},{"key":"1212_CR61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1447-0594.2011.00740.x","volume":"12","author":"F Niwa","year":"2012","unstructured":"Niwa, F., Kuriyama, N., Nakagawa, M. & Imanishi, J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson\u2019s disease. Geriatr. Gerontol. Int. 12, 102\u2013107 (2012).","journal-title":"Geriatr. Gerontol. Int."},{"key":"1212_CR62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.parkreldis.2007.05.013","volume":"14","author":"T Mihara","year":"2008","unstructured":"Mihara, T. et al. Natural killer cells of Parkinson\u2019s disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. Parkinson. Relat. Disord. 14, 46\u201351 (2008).","journal-title":"Parkinson. Relat. Disord."},{"key":"1212_CR63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12264-017-0163-9","volume":"33","author":"L Cen","year":"2017","unstructured":"Cen, L. et al. Peripheral lymphocyte subsets as a marker of parkinson\u2019s disease in a chinese population. Neurosci. Bull. 33, 493\u2013500 (2017).","journal-title":"Neurosci. Bull."},{"key":"1212_CR64","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41375-024-02271-1","volume":"38","author":"M Farhat","year":"2024","unstructured":"Farhat, M. et al. PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL. Leukemia 38, 1813\u20131817 (2024).","journal-title":"Leukemia"},{"key":"1212_CR65","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene 36, 6143\u20136153 (2017).","journal-title":"Oncogene"},{"key":"1212_CR66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce, S. et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J. Allergy Clin. Immunol. 139, 335\u2013346.e333 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1212_CR67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/vim.2011.0096","volume":"25","author":"S Norris","year":"2012","unstructured":"Norris, S. et al. PD-1 expression on natural killer cells and CD8+ T cells during chronic HIV-1 infection. Viral Immunol. 25, 329\u2013332 (2012).","journal-title":"Viral Immunol."},{"key":"1212_CR68","doi-asserted-by":"crossref","unstructured":"Quatrini, L. et al. The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel) 12, 3285 (2020).","DOI":"10.3390\/cancers12113285"},{"key":"1212_CR69","doi-asserted-by":"crossref","unstructured":"Georgoula, M. et al. Sortilin expression levels and peripheral immunity: a potential biomarker for segregation between Parkinson\u2019s disease patients and healthy controls. Int. J. Mol. Sci. 25, 1791 (2024).","DOI":"10.3390\/ijms25031791"},{"key":"1212_CR70","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.18632\/aging.100859","volume":"7","author":"S Horvath","year":"2015","unstructured":"Horvath, S. & Ritz, B. R. Increased epigenetic age and granulocyte counts in the blood of Parkinson\u2019s disease patients. Aging (Albany NY) 7, 1130\u20131142 (2015).","journal-title":"Aging (Albany NY)"},{"key":"1212_CR71","doi-asserted-by":"crossref","unstructured":"Li, R. et al. Abnormal B-cell and Tfh-cell profiles in patients with Parkinson disease: a cross-sectional study. Neurol. Neuroimmunol. Neuroinflamm. 9, e1125 (2022).","DOI":"10.1212\/NXI.0000000000001125"},{"key":"1212_CR72","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad060","volume":"5","author":"KM Scott","year":"2023","unstructured":"Scott, K. M. et al. B lymphocyte responses in Parkinson\u2019s disease and their possible significance in disease progression. Brain Commun. 5, fcad060 (2023).","journal-title":"Brain Commun."},{"key":"1212_CR73","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105890","volume":"116","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Abnormal immune function of B lymphocyte in peripheral blood of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 116, 105890 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1212_CR74","doi-asserted-by":"crossref","unstructured":"Zhao, X., Jin, T., Zheng, C., Ma, D. & Zhang, Y. Imbalance of circulating Tfh\/Tfr cells in patients with Parkinson\u2019s disease. Front. Neurol. 11, 572205 (2020).","DOI":"10.3389\/fneur.2020.572205"},{"key":"1212_CR75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12882-021-02374-2","volume":"22","author":"EH Ibrahim","year":"2021","unstructured":"Ibrahim, E. H. et al. Higher CD19+CD25+ Bregs are independently associated with better graft function in renal transplant recipients. BMC Nephrol. 22, 180 (2021).","journal-title":"BMC Nephrol."},{"key":"1212_CR76","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.autrev.2011.11.018","volume":"11","author":"A Kessel","year":"2012","unstructured":"Kessel, A. et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun. Rev. 11, 670\u2013677 (2012).","journal-title":"Autoimmun. Rev."},{"key":"1212_CR77","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Luqu\u00edn, D. D. et al. Regulatory impairment in untreated Parkinson\u2019s disease is not restricted to Tregs: other regulatory populations are also involved. J. Neuroinflamm. 16, 212 (2019).","DOI":"10.1186\/s12974-019-1606-1"},{"key":"1212_CR78","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2567.2006.02331.x","volume":"117","author":"M Brisslert","year":"2006","unstructured":"Brisslert, M. et al. Phenotypic and functional characterization of human CD25+ B cells. Immunology 117, 548\u2013557 (2006).","journal-title":"Immunology"},{"key":"1212_CR79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tins.2023.07.005","volume":"46","author":"J Lauritsen","year":"2023","unstructured":"Lauritsen, J. & Romero-Ramos, M. The systemic immune response in Parkinson\u2019s disease: focus on the peripheral immune component. Trends Neurosci. 46, 863\u2013878 (2023).","journal-title":"Trends Neurosci."},{"key":"1212_CR80","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2005.03.021","volume":"116","author":"K Kawai","year":"2005","unstructured":"Kawai, K. et al. CD11b-mediated migratory property of peripheral blood B cells. J. Allergy Clin. Immunol. 116, 192\u2013197 (2005).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1212_CR81","doi-asserted-by":"crossref","unstructured":"Wang, P. et al. Global characterization of peripheral B cells in Parkinson\u2019s disease by single-cell RNA and BCR sequencing. Front. Immunol. 13, 814239 (2022).","DOI":"10.3389\/fimmu.2022.814239"},{"key":"1212_CR82","volume":"8","author":"Z Yan","year":"2021","unstructured":"Yan, Z. et al. Dysregulation of the adaptive immune system in patients with early-stage parkinson disease. Neurol. Neuroimmunol. Neuroinflamm 8, e1036 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"1212_CR83","doi-asserted-by":"crossref","unstructured":"Fu, Y. et al. Intestinal CD11b+ B cells ameliorate colitis by secreting immunoglobulin A. Front. Immunol. 12, 697725 (2021).","DOI":"10.3389\/fimmu.2021.697725"},{"key":"1212_CR84","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-021-02296-8","volume":"18","author":"D Bhatia","year":"2021","unstructured":"Bhatia, D. et al. T-cell dysregulation is associated with disease severity in Parkinson\u2019s Disease. J. Neuroinflamm. 18, 250 (2021).","journal-title":"J. Neuroinflamm."},{"key":"1212_CR85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jneuroim.2017.06.004","volume":"310","author":"E Caggiu","year":"2017","unstructured":"Caggiu, E. et al. Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson\u2019s disease. J. Neuroimmunol. 310, 26\u201331 (2017).","journal-title":"J. Neuroimmunol."},{"key":"1212_CR86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41531-017-0010-8","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook, D. A. et al. LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. NPJ Parkinsons Dis. 3, 11 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"1212_CR87","first-page":"182","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard, V. et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119, 182\u2013192 (2009).","journal-title":"J. Clin. Invest."},{"key":"1212_CR88","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/brain\/awaa269","volume":"143","author":"J Galiano-Landeira","year":"2020","unstructured":"Galiano-Landeira, J., Torra, A., Vila, M. & Bov\u00e9, J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain 143, 3717\u20133733 (2020).","journal-title":"Brain"},{"key":"1212_CR89","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s40478-020-01083-5","volume":"8","author":"A Kouli","year":"2020","unstructured":"Kouli, A., Camacho, M., Allinson, K. & Williams-Gray, C. H. Neuroinflammation and protein pathology in Parkinson\u2019s disease dementia. Acta Neuropathol. Commun. 8, 211 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1212_CR90","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3389\/fneur.2018.01081","volume":"9","author":"JB Schroder","year":"2018","unstructured":"Schroder, J. B. et al. Immune cell activation in the cerebrospinal fluid of patients with parkinson\u2019s disease. Front Neurol. 9, 1081 (2018).","journal-title":"Front Neurol."},{"key":"1212_CR91","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clineuro.2018.01.022","volume":"166","author":"E Kouchaki","year":"2018","unstructured":"Kouchaki, E. et al. Increased serum levels of TNF-\u03b1 and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clin. Neurol. Neurosurg. 166, 76\u201379 (2018).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1212_CR92","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","volume":"165","author":"M Mogi","year":"1994","unstructured":"Mogi, M. et al. Tumor necrosis factor-\u03b1 (TNF-\u03b1) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208\u2013210 (1994).","journal-title":"Neurosci. Lett."},{"key":"1212_CR93","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nbd.2012.09.007","volume":"50","author":"D Devos","year":"2013","unstructured":"Devos, D. et al. Colonic inflammation in Parkinson\u2019s disease. Neurobiol. Dis. 50, 42\u201348 (2013).","journal-title":"Neurobiol. Dis."},{"key":"1212_CR94","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S0317167100012695","volume":"39","author":"C Ketan","year":"2012","unstructured":"Ketan, C., Xiao, Z. & Ben-yan, L. Cytokine gene polymorphisms and Parkinson\u2019s disease: a meta-analysis. Can. J. Neurol. Sci. 39, 58\u201364 (2012).","journal-title":"Can. J. Neurol. Sci."},{"key":"1212_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(01)02111-5","volume":"311","author":"M Nishimura","year":"2001","unstructured":"Nishimura, M. et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson\u2019s disease. Neurosci. Lett. 311, 1\u20134 (2001).","journal-title":"Neurosci. Lett."},{"key":"1212_CR96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neulet.2017.08.049","volume":"658","author":"JD Lindenau","year":"2017","unstructured":"Lindenau, J. D., Altmann, V., Schumacher-Schuh, A. F., Rieder, C. R. & Hutz, M. H. Tumor necrosis factor alpha polymorphisms are associated with Parkinson\u2019s disease age at onset. Neurosci. Lett. 658, 133\u2013136 (2017).","journal-title":"Neurosci. Lett."},{"key":"1212_CR97","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter, I. et al. Anti-tumor necrosis factor therapy and incidence of parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 75, 939\u2013946 (2018).","journal-title":"JAMA Neurol."},{"key":"1212_CR98","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"XY Qin","year":"2016","unstructured":"Qin, X. Y., Zhang, S. P., Cao, C., Loh, Y. P. & Cheng, Y. Aberrations in peripheral inflammatory cytokine levels in parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 73, 1316\u20131324 (2016).","journal-title":"JAMA Neurol."},{"key":"1212_CR99","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/cei.12277","volume":"176","author":"NE Serriari","year":"2014","unstructured":"Serriari, N. E. et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin. Exp. Immunol. 176, 266\u2013274 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"1212_CR100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nature11813","volume":"494","author":"CSN Klose","year":"2013","unstructured":"Klose, C. S. N. et al. A T-bet gradient controls the fate and function of CCR6\u2212ROR\u03b3t+ innate lymphoid cells. Nature 494, 261\u2013265 (2013).","journal-title":"Nature"},{"key":"1212_CR101","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/eji.200525983","volume":"35","author":"N Caccamo","year":"2005","unstructured":"Caccamo, N. et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human V\u03b39V\u03b42 naive, memory and effector T\u2004cell subsets. Eur. J. Immunol. 35, 1764\u20131772 (2005).","journal-title":"Eur. J. Immunol."},{"key":"1212_CR102","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20030235","volume":"198","author":"F Dieli","year":"2003","unstructured":"Dieli, F. et al. Differentiation of effector\/memory V\u03b42 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med. 198, 391\u2013397 (2003).","journal-title":"J. Exp. Med."},{"key":"1212_CR103","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2829","volume":"14","author":"H Andrlov\u00e1","year":"2022","unstructured":"Andrlov\u00e1, H. et al. MAIT and V\u03b42 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Sci. Transl. Med. 14, eabj2829 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1212_CR104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-025-00827-y","volume":"20","author":"JR Mark","year":"2025","unstructured":"Mark, J. R. & Tansey, M. G. Immune cell metabolic dysfunction in Parkinson\u2019s disease. Mol. Neurodegener. 20, 36 (2025).","journal-title":"Mol. Neurodegener."},{"key":"1212_CR105","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3390\/nu13041238","volume":"13","author":"DA Bonilla","year":"2021","unstructured":"Bonilla, D. A. et al. Metabolic basis of creatine in health and disease: a bioinformatics-assisted review. Nutrients 13, 1238 (2021).","journal-title":"Nutrients"},{"key":"1212_CR106","doi-asserted-by":"crossref","unstructured":"Pathan, M., Wu, J., Lakso, H.-\u00c5., Forsgren, L. & \u00d6hman, A. Plasma metabolite markers of Parkinson\u2019s disease and atypical parkinsonism. Metabolites 11, 860 (2021).","DOI":"10.3390\/metabo11120860"},{"key":"1212_CR107","volume":"13","author":"JT Guan","year":"2022","unstructured":"Guan, J. T. et al. Proton magnetic resonance spectroscopy for diagnosis of non-motor symptoms in Parkinson\u2019s disease. Front Neurol. 13, 594711 (2022).","journal-title":"Front Neurol."},{"key":"1212_CR108","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1042\/BCJ20160822","volume":"474","author":"S Br\u00f6er","year":"2017","unstructured":"Br\u00f6er, S. & Br\u00f6er, A. Amino acid homeostasis and signalling in mammalian cells and organisms. Biochem J. 474, 1935\u20131963 (2017).","journal-title":"Biochem J."},{"key":"1212_CR109","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JPD-140389","volume":"4","author":"M Trupp","year":"2014","unstructured":"Trupp, M. et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed parkinson\u2019s disease. J. Parkinsons Dis. 4, 549\u2013560 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"1212_CR110","volume":"10","author":"X-Y Li","year":"2024","unstructured":"Li, X.-Y. et al. Pyruvate is modified by tea\/coffee metabolites and reversely correlated with multiple system atrophy and Parkinson\u2019s disease. Heliyon 10, e26588 (2024).","journal-title":"Heliyon"},{"key":"1212_CR111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1423-0127-16-63","volume":"16","author":"SS Ahmed","year":"2009","unstructured":"Ahmed, S. S., Santosh, W., Kumar, S. & Christlet, H. T. Metabolic profiling of Parkinson\u2019s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci. 16, 63 (2009).","journal-title":"J. Biomed. Sci."},{"key":"1212_CR112","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41531-022-00312-z","volume":"8","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 48 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1212_CR113","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.parkreldis.2022.01.005","volume":"95","author":"E De Pablo-Fernandez","year":"2022","unstructured":"De Pablo-Fernandez, E. et al. The faecal metabolome and mycobiome in Parkinson\u2019s disease. Parkinson. Relat. Disord. 95, 65\u201369 (2022).","journal-title":"Parkinson. Relat. Disord."},{"key":"1212_CR114","doi-asserted-by":"crossref","first-page":"e0191670","DOI":"10.1371\/journal.pone.0191670","volume":"13","author":"M Figura","year":"2018","unstructured":"Figura, M. et al. Serum amino acid profile in patients with Parkinson\u2019s disease. PLoS One 13, e0191670 (2018).","journal-title":"PLoS One"},{"key":"1212_CR115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-nutr-071816-064916","volume":"37","author":"JC Newman","year":"2017","unstructured":"Newman, J. C. & Verdin, E. \u03b2-Hydroxybutyrate: A signaling metabolite. Annu Rev. Nutr. 37, 51\u201376 (2017).","journal-title":"Annu Rev. Nutr."},{"key":"1212_CR116","doi-asserted-by":"crossref","unstructured":"Norwitz, N. G., Hu, M. T. & Clarke, K. The mechanisms by which the ketone body d-\u03b2-hydroxybutyrate may improve the multiple cellular pathologies of parkinson\u2019s disease. Front. Nutr. 6, 63 (2019).","DOI":"10.3389\/fnut.2019.00063"},{"key":"1212_CR117","doi-asserted-by":"crossref","unstructured":"Gonzalez-Riano, C. et al. Prognostic biomarkers of Parkinson\u2019s disease in the Spanish EPIC cohort: a multiplatform metabolomics approach. NPJ Parkinsons Dis. 7, 73 (2021).","DOI":"10.1038\/s41531-021-00216-4"},{"key":"1212_CR118","doi-asserted-by":"crossref","unstructured":"Mallet, D. et al. A metabolic biomarker predicts Parkinson\u2019s disease at the early stages in patients and animal models. J. Clin. Invest. 132, e146400 (2022).","DOI":"10.1172\/JCI146400"},{"key":"1212_CR119","volume":"113","author":"Z Jiang","year":"2022","unstructured":"Jiang, Z. et al. \u03b2-Hydroxybutyrate alleviates pyroptosis in MPP(+)\/MPTP-induced Parkinson\u2019s disease models via inhibiting STAT3\/NLRP3\/GSDMD pathway. Int. Immunopharmacol. 113, 109451 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"1212_CR120","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1073\/pnas.97.10.5440","volume":"97","author":"Y Kashiwaya","year":"2000","unstructured":"Kashiwaya, Y. et al. d-\u03b2-Hydroxybutyrate protects neurons in models of Alzheimer\u2019s and Parkinson\u2019s disease. Proc. Natl. Acad. Sci. USA 97, 5440\u20135444 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1212_CR121","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/mds.104","volume":"33","author":"AM Smith","year":"2018","unstructured":"Smith, A. M. et al. Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson\u2019s blood cells. Mov. Disord. 33, 1580\u20131590 (2018).","journal-title":"Mov. Disord."},{"key":"1212_CR122","volume":"11","author":"D Doi","year":"2020","unstructured":"Doi, D. et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson\u2019s disease. Nat. Commun. 11, 3369 (2020).","journal-title":"Nat. Commun."},{"key":"1212_CR123","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105780","volume":"170","author":"RM Voigt","year":"2022","unstructured":"Voigt, R. M. et al. Gut microbial metabolites in Parkinson\u2019s disease: association with lifestyle, disease characteristics, and treatment status. Neurobiol. Dis. 170, 105780 (2022).","journal-title":"Neurobiol. Dis."},{"key":"1212_CR124","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41396-018-0068-2","volume":"12","author":"C Serena","year":"2018","unstructured":"Serena, C. et al. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J. 12, 1642\u20131657 (2018).","journal-title":"ISME J."},{"key":"1212_CR125","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.celrep.2018.04.104","volume":"23","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Accumulation of succinate in cardiac ischemia primarily occurs via canonical krebs cycle activity. Cell Rep. 23, 2617\u20132628 (2018).","journal-title":"Cell Rep."},{"key":"1212_CR126","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41385-018-0087-3","volume":"12","author":"DC Macias-Ceja","year":"2019","unstructured":"Macias-Ceja, D. C. et al. Succinate receptor mediates intestinal inflammation and fibrosis. Mucosal Immunol. 12, 178\u2013187 (2019).","journal-title":"Mucosal Immunol."},{"key":"1212_CR127","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00011-011-0340-7","volume":"60","author":"M Ooi","year":"2011","unstructured":"Ooi, M. et al. GC\/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm. Res. 60, 831\u2013840 (2011).","journal-title":"Inflamm. Res."},{"key":"1212_CR128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.mito.2010.03.001","volume":"10","author":"J Rutter","year":"2010","unstructured":"Rutter, J., Winge, D. R. & Schiffman, J. D. Succinate dehydrogenase \u2013 assembly, regulation and role in human disease. Mitochondrion 10, 393\u2013401 (2010).","journal-title":"Mitochondrion"},{"key":"1212_CR129","doi-asserted-by":"crossref","first-page":"i288","DOI":"10.1093\/ecco-jcc\/jjae190.0151","volume":"19","author":"GR Jones","year":"2025","unstructured":"Jones, G. R. et al. DOP112 Inflammation-associated monocytes express ACOD1 to curtail inflammatory behaviour in IBD and experimental colitis. J. Crohn\u2019s Colitis 19, i288\u2013i289 (2025).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"1212_CR130","doi-asserted-by":"crossref","unstructured":"Kim, H. W. et al. Aconitate decarboxylase 1 deficiency exacerbates mouse colitis induced by dextran sodium sulfate. Int. J. Mol. Sci. 23, 4392 (2022).","DOI":"10.3390\/ijms23084392"},{"key":"1212_CR131","volume":"15","author":"YH Wei","year":"2023","unstructured":"Wei, Y. H., Ma, X., Zhao, J. C., Wang, X. Q. & Gao, C. Q. Succinate metabolism and its regulation of host-microbe interactions. Gut Microbes 15, 2190300 (2023).","journal-title":"Gut Microbes"},{"key":"1212_CR132","doi-asserted-by":"crossref","unstructured":"Connors, J., Dawe, N. & Van Limbergen, J. The role of succinate in the regulation of intestinal inflammation. Nutrients 11, 25 (2018).","DOI":"10.3390\/nu11010025"},{"key":"1212_CR133","doi-asserted-by":"crossref","unstructured":"Vascellari, S. et al. Gut microbiota and metabolome alterations associated with Parkinson's disease. mSystems 5, e00561-20 (2020).","DOI":"10.1128\/mSystems.00561-20"},{"key":"1212_CR134","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jcmgh.2016.02.003","volume":"2","author":"H Nagao-Kitamoto","year":"2016","unstructured":"Nagao-Kitamoto, H. et al. Functional characterization of inflammatory bowel disease-associated gut dysbiosis in gnotobiotic mice. Cell Mol. Gastroenterol. Hepatol. 2, 468\u2013481 (2016).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1212_CR135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1126\/science.aag2029","volume":"356","author":"YG Kim","year":"2017","unstructured":"Kim, Y. G. et al. Neonatal acquisition of Clostridia species protects against colonization by bacterial pathogens. Science 356, 315\u2013319 (2017).","journal-title":"Science"},{"key":"1212_CR136","doi-asserted-by":"crossref","unstructured":"Fusco, W. et al. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients 15, 2211 (2023).","DOI":"10.3390\/nu15092211"},{"key":"1212_CR137","doi-asserted-by":"crossref","unstructured":"Baj, A. et al. Glutamatergic signaling along the microbiota-gut-brain axis. Int. J. Mol. Sci. 20, 1482 (2019).","DOI":"10.3390\/ijms20061482"},{"key":"1212_CR138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11302-015-9480-5","volume":"12","author":"L K\u00f6les","year":"2016","unstructured":"K\u00f6les, L. et al. Modulation of excitatory neurotransmission by neuronal\/glial signalling molecules: interplay between purinergic and glutamatergic systems. Purinergic Signal 12, 1\u201324 (2016).","journal-title":"Purinergic Signal"},{"key":"1212_CR139","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ana.25982","volume":"89","author":"AH Tan","year":"2021","unstructured":"Tan, A. H. et al. Gut microbial ecosystem in parkinson disease: new clinicobiological insights from multi-omics. Ann. Neurol. 89, 546\u2013559 (2021).","journal-title":"Ann. Neurol."},{"key":"1212_CR140","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/nar\/gkv047","volume":"43","author":"AN Lane","year":"2015","unstructured":"Lane, A. N. & Fan, T. W. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 43, 2466\u20132485 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1212_CR141","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/j.2040-4603.2018.tb00034.x","volume":"8","author":"M Pastor-Anglada","year":"2018","unstructured":"Pastor-Anglada, M., Urtasun, N. & P\u00e9rez-Torras, S. Intestinal nucleoside transporters: function, expression, and regulation. Compr. Physiol. 8, 1003\u20131017 (2018).","journal-title":"Compr. Physiol."},{"key":"1212_CR142","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","volume":"150","author":"A Habtezion","year":"2016","unstructured":"Habtezion, A., Nguyen, L. P., Hadeiba, H. & Butcher, E. C. Leukocyte trafficking to the small intestine and colon. Gastroenterology 150, 340\u2013354 (2016).","journal-title":"Gastroenterology"},{"key":"1212_CR143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00394-017-1445-8","volume":"57","author":"I Rowland","year":"2018","unstructured":"Rowland, I. et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur. J. Nutr. 57, 1\u201324 (2018).","journal-title":"Eur. J. Nutr."},{"key":"1212_CR144","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2022-328166","volume":"72","author":"N Proch\u00e1zkov\u00e1","year":"2023","unstructured":"Proch\u00e1zkov\u00e1, N. et al. Advancing human gut microbiota research by considering gut transit time. Gut 72, 180\u2013191 (2023).","journal-title":"Gut"},{"key":"1212_CR145","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10663-w","volume":"7","author":"L Mancabelli","year":"2017","unstructured":"Mancabelli, L. et al. Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses. Sci. Rep. 7, 9879 (2017).","journal-title":"Sci. Rep."},{"key":"1212_CR146","volume":"377","author":"J-Y Lee","year":"2022","unstructured":"Lee, J.-Y., Tsolis, R. M. & B\u00e4umler, A. J. The microbiome and gut homeostasis. Science 377, eabp9960 (2022).","journal-title":"Science"},{"key":"1212_CR147","doi-asserted-by":"crossref","DOI":"10.1186\/cc11413","volume":"16","author":"A Osuka","year":"2012","unstructured":"Osuka, A. et al. Prognostic impact of fecal pH in critically ill patients. Crit. Care 16, R119 (2012).","journal-title":"Crit. Care"},{"key":"1212_CR148","doi-asserted-by":"crossref","unstructured":"Bruggeman, A. et al. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson\u2019s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine 71, 102563 (2024).","DOI":"10.1016\/j.eclinm.2024.102563"},{"key":"1212_CR149","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jamaneurol.2024.2305","volume":"81","author":"F Scheperjans","year":"2024","unstructured":"Scheperjans, F. et al. Fecal microbiota transplantation for treatment of parkinson disease: a randomized clinical trial. JAMA Neurol. 81, 925\u2013938 (2024).","journal-title":"JAMA Neurol."},{"key":"1212_CR150","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/ecco-jcc\/jjad151","volume":"17","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens, G. et al. Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in crohn\u2019s disease patients: a prospective open-label study. J. Crohns Colitis 17, 1897\u20131909 (2023).","journal-title":"J. Crohns Colitis"},{"key":"1212_CR151","doi-asserted-by":"crossref","unstructured":"Lench, D. H. et al. Multi-session transcutaneous auricular vagus nerve stimulation for Parkinson\u2019s disease: evaluating feasibility, safety, and preliminary efficacy. Front. Neurol. 14, 1210103 (2023).","DOI":"10.3389\/fneur.2023.1210103"},{"key":"1212_CR152","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-023-03081-1","volume":"23","author":"HP Sigurdsson","year":"2023","unstructured":"Sigurdsson, H. P. et al. Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson\u2019s: a study protocol. BMC Neurol. 23, 58 (2023).","journal-title":"BMC Neurol."},{"key":"1212_CR153","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00415-020-10367-8","volume":"268","author":"MC Bakeberg","year":"2021","unstructured":"Bakeberg, M. C. et al. Differential effects of sex on longitudinal patterns of cognitive decline in Parkinson\u2019s disease. J. Neurol. 268, 1903\u20131912 (2021).","journal-title":"J. Neurol."},{"key":"1212_CR154","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1008841022998","volume":"7","author":"DA Revicki","year":"1998","unstructured":"Revicki, D. A., Wood, M., Wiklund, I. & Crawley, J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual. Life Res. 7, 75\u201383 (1998).","journal-title":"Qual. Life Res."},{"key":"1212_CR155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-6-12","volume":"6","author":"KR Kulich","year":"2008","unstructured":"Kulich, K. R. et al. Reliability and validity of the gastrointestinal symptom rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual. Life Outcomes 6, 12 (2008).","journal-title":"Health Qual. Life Outcomes"},{"key":"1212_CR156","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","volume":"33","author":"J Svedlund","year":"1988","unstructured":"Svedlund, J., Sj\u00f6din, I. & Dotevall, G. GSRS\u2014A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 33, 129\u2013134 (1988).","journal-title":"Dig. Dis. Sci."},{"key":"1212_CR157","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"1212_CR158","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism. Neurology 17, 427\u2013427 (1967).","journal-title":"Neurology"},{"key":"1212_CR159","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"1212_CR160","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1021\/ac5025039","volume":"86","author":"AC Dona","year":"2014","unstructured":"Dona, A. C. et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal. Chem. 86, 9887\u20139894 (2014).","journal-title":"Anal. Chem."},{"key":"1212_CR161","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1021\/acs.analchem.5b04159","volume":"88","author":"J Gratton","year":"2016","unstructured":"Gratton, J. et al. Optimized sample handling strategy for metabolic profiling of human feces. Anal. Chem. 88, 4661\u20134668 (2016).","journal-title":"Anal. Chem."},{"key":"1212_CR162","doi-asserted-by":"crossref","first-page":"11962","DOI":"10.1021\/acs.analchem.8b02412","volume":"90","author":"B Jim\u00e9nez","year":"2018","unstructured":"Jim\u00e9nez, B. et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by (1)H NMR spectroscopy in a multilaboratory trial. Anal. Chem. 90, 11962\u201311971 (2018).","journal-title":"Anal. Chem."},{"key":"1212_CR163","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/ac00101a004","volume":"67","author":"JK Nicholson","year":"1995","unstructured":"Nicholson, J. K., Foxall, P. J., Spraul, M., Farrant, R. D. & Lindon, J. C. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal. Chem. 67, 793\u2013811 (1995).","journal-title":"Anal. Chem."},{"key":"1212_CR164","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1021\/ac981422i","volume":"71","author":"S Akoka","year":"1999","unstructured":"Akoka, S., Barantin, L. & Trierweiler, M. Concentration Measurement by Proton NMR Using the ERETIC Method. Anal. Chem. 71, 2554\u20132557 (1999).","journal-title":"Anal. Chem."},{"key":"1212_CR165","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1093\/bioinformatics\/bty528","volume":"34","author":"J Chong","year":"2018","unstructured":"Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 34, 4313\u20134314 (2018).","journal-title":"Bioinformatics"},{"key":"1212_CR166","volume":"6","author":"SJD O\u2019Keefe","year":"2015","unstructured":"O\u2019Keefe, S. J. D. et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat. Commun. 6, 6342 (2015).","journal-title":"Nat. Commun."},{"key":"1212_CR167","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1136\/gutjnl-2015-309957","volume":"65","author":"F De Filippis","year":"2016","unstructured":"De Filippis, F. et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 65, 1812\u20131821 (2016).","journal-title":"Gut"},{"key":"1212_CR168","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"2018","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289\u2013300 (2018).","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"1212_CR169","first-page":"1","volume":"2","author":"H Wickham","year":"2016","unstructured":"Wickham, H., Chang, W. & Wickham, M. H. Package \u2018ggplot2\u2019. Create elegant data visualisations using the grammar of graphics. Version 2, 1\u2013189 (2016).","journal-title":"Version"},{"key":"1212_CR170","unstructured":"Kassambara, A. ggpubr:\u2018ggplot2\u2019Based Publication Ready Plots. https:\/\/rpkgs.datanovia.com\/ggpubr\/ (2018)."},{"key":"1212_CR171","doi-asserted-by":"crossref","unstructured":"Wilke, C. O. & Wiernik, B. M. ggtext: Improved Text Rendering Support for \u2018ggplot2\u2019. https:\/\/wilkelab.org\/ggtext\/ (2020).","DOI":"10.32614\/CRAN.package.ggtext"},{"key":"1212_CR172","volume":"12","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Use ggbreak to effectively utilize plotting space to deal with large datasets and outliers. Front. Genet. 12, 774846 (2021).","journal-title":"Front. Genet."},{"key":"1212_CR173","unstructured":"Kassambara, A. & Mundt, F. Package \u2018factoextra\u2019. https:\/\/cran.r-project.org\/web\/packages\/factoextra\/readme\/README.html (2017)."},{"key":"1212_CR174","first-page":"790","volume":"1","author":"R Kolde","year":"2015","unstructured":"Kolde, R. & Kolde, M. R. Package \u2018pheatmap\u2019. R. package 1, 790 (2015).","journal-title":"R. package"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01212-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01212-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01212-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:03:43Z","timestamp":1767477823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01212-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":174,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01212-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}